Fortrea to divest Endpoint Clinical, Fortrea Patient Access to Arsenal Capital

Fortre has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners. By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the technology roadmap and further enhance operations to support best-in-class customer solutions and delivery. The remaining business of Fortrea will strengthen its focus on clinical development phases 1 through 4. Closing is targeted for the second quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.